Corneodermatoosseous syndrome

Corneodermatoosseous syndrome (CDO syndrome) is an extremely rare genetic disorder characterized by a triad of abnormalities affecting the cornea, skin, and bones. The condition was first described in a single family and involves corneal dystrophy (clouding or opacification of the cornea leading to visual impairment), skin abnormalities including palmoplantar keratoderma (thickening of the skin on the palms and soles), and skeletal anomalies such as brachydactyly (short fingers and toes) and other bone malformations. The corneal changes, classified under hereditary corneal dystrophies (ICD-10: H18.5), can be progressive and may significantly affect vision over time. Additional features that have been reported include hypotrichosis (sparse hair), nail dystrophy, and dental anomalies, reflecting the ectodermal involvement of this syndrome. The skeletal manifestations may include short stature and abnormalities of the digits. Because of its extreme rarity, the molecular genetic basis of corneodermatoosseous syndrome has not been fully elucidated, though autosomal dominant inheritance has been suggested based on the observed family pedigree. There is no specific cure or targeted therapy for corneodermatoosseous syndrome. Management is symptomatic and supportive, involving ophthalmologic care for corneal dystrophy (which may include corneal transplantation in severe cases), dermatologic treatment for keratoderma (emollients, keratolytic agents), and orthopedic monitoring for skeletal abnormalities. A multidisciplinary approach involving ophthalmologists, dermatologists, orthopedic specialists, and clinical geneticists is recommended for optimal patient care.

Common questions about Corneodermatoosseous syndrome